{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T07:17:18Z","timestamp":1792048638019,"version":"4.4.0"},"reference-count":42,"publisher":"The Journal of Rheumatology","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2019,9]]},"abstract":"\n Objective.<\/jats:title>\n To determine whether neutropenia is associated with increased risk for infection in patients with systemic juvenile idiopathic arthritis (sJIA) and polyarticular-course juvenile idiopathic arthritis (pcJIA) treated with tocilizumab (TCZ).<\/jats:p>\n <\/jats:sec>\n \n Methods.<\/jats:title>\n \n Data up to Week 104 from 2 phase III trials of intravenous TCZ in sJIA (n = 112;\n ClinicalTrials.gov<\/jats:ext-link>\n ,\n NCT00642460<\/jats:ext-link>\n ) and pcJIA (n = 188;\n ClinicalTrials.gov<\/jats:ext-link>\n ,\n NCT00988221<\/jats:ext-link>\n ) were pooled. Worst common toxicity criteria grade and lowest observed absolute neutrophil count (ANC) were identified for each patient. Associations between patient characteristics and lowest observed ANC were tested using univariate regression analysis. Infection and serious infection rates per 100 patient-years (PY) in periods associated with grades 1\/2 and 3\/4 neutrophil counts were compared with rates associated with normal neutrophil counts.\n <\/jats:p>\n <\/jats:sec>\n \n Results.<\/jats:title>\n ANC decreased to grade \u2265 3 in 25.0% and 5.9% of sJIA and pcJIA patients, respectively, and decreases were transient. Young age (p = 0.047) and methotrexate use (p = 0.012) were positively associated with neutropenia in patients with sJIA but not in patients with pcJIA. The rate of serious infections in patients with sJIA (10.9\/100 PY; 95% CI 6.8\u201316.5) tended to be higher than in patients with pcJIA (5.2\/100 PY; 95% CI 3\u20138.5). No increase in rates of serious or nonserious infections was observed during periods of neutropenia in either trial.<\/jats:p>\n <\/jats:sec>\n \n Conclusion.<\/jats:title>\n Patients with JIA treated with TCZ experienced transient neutropenia that was not associated with an increased number of infections.<\/jats:p>\n <\/jats:sec>","DOI":"10.3899\/jrheum.180795","type":"journal-article","created":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T12:24:15Z","timestamp":1551443055000},"page":"1117-1126","source":"Crossref","is-referenced-by-count":21,"title":["Neutropenia During Tocilizumab Treatment Is Not Associated with Infection Risk in Systemic or Polyarticular-course Juvenile Idiopathic Arthritis"],"prefix":"10.3899","volume":"46","author":[{"given":"Manuela","family":"Pardeo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianmei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8407-7782","authenticated-orcid":false,"given":"Nicolino","family":"Ruperto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterina","family":"Alexeeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vyacheslav","family":"Chasnyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rayfel","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd","family":"Horneff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Iko","family":"Huppertz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten","family":"Minden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Onel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Zemel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Kon\u00e9-Paut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antigoni","family":"Siamopoulou-Mavridou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clovis A.","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Porter-Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamal N.","family":"Bharucha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermine I.","family":"Brunner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"De Benedetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2019,3,1]]},"reference":[{"key":"2019090109250729000_46.9.1117.1","doi-asserted-by":"publisher","DOI":"10.1186\/ar1969"},{"key":"2019090109250729000_46.9.1117.2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu035"},{"key":"2019090109250729000_46.9.1117.3","doi-asserted-by":"publisher","DOI":"10.1002\/art.22033"},{"key":"2019090109250729000_46.9.1117.4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60453-5"},{"key":"2019090109250729000_46.9.1117.5","doi-asserted-by":"publisher","DOI":"10.1002\/art.23940"},{"key":"2019090109250729000_46.9.1117.6","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.092932"},{"key":"2019090109250729000_46.9.1117.7","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.105197"},{"key":"2019090109250729000_46.9.1117.8","doi-asserted-by":"publisher","DOI":"10.1002\/art.30158"},{"key":"2019090109250729000_46.9.1117.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1613849"},{"key":"2019090109250729000_46.9.1117.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112802"},{"key":"2019090109250729000_46.9.1117.11","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1136\/annrheumdis-2014-205351","article-title":"Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial","volume":"74","author":"Brunner","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2019090109250729000_46.9.1117.12","unstructured":"Cancer Therapy Evaluation Program . Common Terminology Criteria for Adverse Events v3.0 (CTCAE). [Internet. Accessed March 5, 2019.] Available from: ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcaev3.pdf."},{"key":"2019090109250729000_46.9.1117.13","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.120687"},{"key":"2019090109250729000_46.9.1117.14","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1002\/art.38461","article-title":"Neutropenia with tocilizumab treatment is not associated with increased infection risk in patients with polyarticular-course juvenile idiopathic arthritis","volume":"66","author":"De Benedetti","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"Suppl 10","key":"2019090109250729000_46.9.1117.15","first-page":"S114","article-title":"Neutropenia with tocilizumab treatment is not associated with increased infection risk in patients with systemic juvenile idiopathic arthritis","volume":"65","author":"De Benedetti","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2019090109250729000_46.9.1117.16","first-page":"541","article-title":"Effect of tocilizumab on neutrophils in adult patients with rheumatoid arthritis: pooled analysis of data from phase 3 and 4 clinical trials","volume":"56","author":"Moots","year":"2017","journal-title":"Rheumatology"},{"key":"2019090109250729000_46.9.1117.17","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204405"},{"key":"2019090109250729000_46.9.1117.18","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1182\/blood.V73.7.1828.1828","article-title":"Interleukin-6 interacts with interleukin-4 and other hematopoietic growth factors to selectively enhance the growth of megakaryocytic, erythroid, myeloid, and multipotential progenitor cells","volume":"73","author":"Rennick","year":"1989","journal-title":"Blood"},{"key":"2019090109250729000_46.9.1117.19","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1182\/blood.V90.7.2583.2583_2583_2590","article-title":"Interleukin-6 and the granulocyte colony-stimulating factor receptor are major independent regulators of granulopoiesis in vivo but are not required for lineage commitment or terminal differentiation","volume":"90","author":"Liu","year":"1997","journal-title":"Blood"},{"key":"2019090109250729000_46.9.1117.20","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-011-9227-z"},{"key":"2019090109250729000_46.9.1117.21","doi-asserted-by":"crossref","first-page":"H2954","DOI":"10.1152\/ajpheart.2000.279.6.H2954","article-title":"Interleukin-6 induces demargination of intravascular neutrophils and shortens their transit in marrow","volume":"279","author":"Suwa","year":"2000","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2019090109250729000_46.9.1117.22","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/eci.12799","article-title":"Effects of tocilizumab on neutrophil function and kinetics","volume":"47","author":"Lok","year":"2017","journal-title":"Eur J Clin Invest"},{"key":"2019090109250729000_46.9.1117.23","first-page":"390","article-title":"International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001","volume":"31","author":"Petty","year":"2004","journal-title":"J Rheumatol"},{"key":"2019090109250729000_46.9.1117.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2010.07.021"},{"key":"2019090109250729000_46.9.1117.25","doi-asserted-by":"publisher","DOI":"10.1007\/s10165-010-0279-5"},{"key":"2019090109250729000_46.9.1117.26","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200008)43:8<1849::AID-ANR22>3.0.CO;2-F"},{"key":"2019090109250729000_46.9.1117.27","doi-asserted-by":"publisher","DOI":"10.2174\/138945011794751555"},{"key":"2019090109250729000_46.9.1117.28","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-146-7-200704030-00004"},{"key":"2019090109250729000_46.9.1117.29","doi-asserted-by":"publisher","DOI":"10.1002\/art.30128"},{"key":"2019090109250729000_46.9.1117.30","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.134254"},{"key":"2019090109250729000_46.9.1117.31","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13075-016-1109-8","article-title":"The risk of hospitalized infection following initiation of biologic agents versus methotrexate in the treatment of juvenile idiopathic arthritis","volume":"18","author":"Beukelman","year":"2016","journal-title":"Arthritis Res Ther"},{"issue":"Suppl 10","key":"2019090109250729000_46.9.1117.32","first-page":"3116","article-title":"Risk of infections in juvenile idiopathic arthritis patients treated with biologic agents and\/or methotrexate: results from Pharmachild Registry","volume":"68","author":"Giancane","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2019090109250729000_46.9.1117.33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0706290"},{"key":"2019090109250729000_46.9.1117.34","doi-asserted-by":"publisher","DOI":"10.1002\/art.21885"},{"key":"2019090109250729000_46.9.1117.35","doi-asserted-by":"publisher","DOI":"10.1002\/art.34458"},{"key":"2019090109250729000_46.9.1117.36","doi-asserted-by":"publisher","DOI":"10.1002\/art.10524"},{"key":"2019090109250729000_46.9.1117.37","doi-asserted-by":"publisher","DOI":"10.1002\/art.10529"},{"key":"2019090109250729000_46.9.1117.38","first-page":"387","article-title":"The risk of hospitalized infection in patients with rheumatoid arthritis","volume":"35","author":"Smitten","year":"2008","journal-title":"J Rheumatol"},{"key":"2019090109250729000_46.9.1117.39","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kem076"},{"key":"2019090109250729000_46.9.1117.40","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e3182814b5a"},{"key":"2019090109250729000_46.9.1117.41","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2011.01.007"},{"key":"2019090109250729000_46.9.1117.42","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.163.4.2005132"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.180795","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T15:54:27Z","timestamp":1574178867000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.180795"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,1]]},"references-count":42,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2019,9,1]]},"published-print":{"date-parts":[[2019,9]]}},"alternative-id":["10.3899\/jrheum.180795"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.180795","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,1]]}}}